GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Operating Income

Aquestive Therapeutics (Aquestive Therapeutics) Operating Income : $-19.45 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Operating Income?

Aquestive Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-8.96 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-19.45 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Aquestive Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-8.96 Mil. Aquestive Therapeutics's Revenue for the three months ended in Mar. 2024 was $12.05 Mil. Therefore, Aquestive Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was -74.31%.

Good Sign:

Aquestive Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

Aquestive Therapeutics's 5-Year average Growth Rate for Operating Margin % was 13.70% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aquestive Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 was -161.27%. Aquestive Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -359.05%.


Aquestive Therapeutics Operating Income Historical Data

The historical data trend for Aquestive Therapeutics's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics Operating Income Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial -52.67 -42.89 -34.68 -42.07 -15.10

Aquestive Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.61 -4.21 -2.38 -3.91 -8.96

Aquestive Therapeutics Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aquestive Therapeutics  (NAS:AQST) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aquestive Therapeutics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-35.828 * ( 1 - 0% )/( (23.539 + 20.894)/ 2 )
=-35.828/22.2165
=-161.27 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Aquestive Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-34.512/( ( (9.736 + max(-3.703, 0)) + (9.488 + max(-1.063, 0)) )/ 2 )
=-34.512/( ( 9.736 + 9.488 )/ 2 )
=-34.512/9.612
=-359.05 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.57 + 6.769 + 1.854) - (11.221 + 1.551 + 5.124)
=-3.703

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.703 + 7.734 + 2.121) - (13.429 + 1.551 + 2.641)
=-1.063

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Aquestive Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-8.957/12.053
=-74.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Aquestive Therapeutics Operating Income Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki officer: SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung officer: SVP, Operations C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt officer: Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd officer: SVP-Operations/Value Delivery 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender officer: SVP, General Counsel 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber officer: SVP-Chief Strategy/Dev Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel director, officer: Chief Innovation/Tech Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr officer: Interim CFO
John T. Maxwell officer: SVP-Chief Financial Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall director, officer: President and CEO 30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta director C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154

Aquestive Therapeutics (Aquestive Therapeutics) Headlines

From GuruFocus